LCM
MREO

Lynwood Capital Management’s Mereo BioPharma MREO Stock Holding History

Lynwood Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$57.8K – 73
2023
Q4 		$57.8K Buy
+25,000
New +$47.8K 0.25% 27

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Lynwood Capital Management's MREO Position: Q1 2024 in Review

Lynwood Capital Management sold out of Mereo BioPharma (MREO) in Q1 2024, closing a stake of 25,000 shares — an estimated $57.8K sold.

Lynwood Capital Management first reported a position in MREO in Q4 2023 and held it in 1 quarter. The position peaked at $57.8K in Q4 2023. 80 funds tracked by Wall St. Rank hold MREO as of Q1 2024.

  • Lynwood Capital Management reported no remaining Mereo BioPharma position as of Q1 2024 after selling out during the quarter.
  • Lynwood Capital Management sold 25,000 Mereo BioPharma shares in Q1 2024, an estimated $57.8K.
  • Lynwood Capital Management first reported a position in Mereo BioPharma in Q4 2023 and held it in 1 quarter.
  • Lynwood Capital Management's Mereo BioPharma position peaked at $57.8K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2024.

Based on Lynwood Capital Management's 13F filing for Q1 2024, filed 10 May 2024.